uniQure (NASDAQ:QURE) Stock Price Passes Below 200 Day Moving Average of $5.72

uniQure (NASDAQ:QUREGet Free Report)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.72 and traded as low as $5.29. uniQure shares last traded at $5.31, with a volume of 324,131 shares.

Analyst Ratings Changes

Several research firms have recently commented on QURE. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Friday, March 1st. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of uniQure in a research report on Wednesday, May 8th. The Goldman Sachs Group lowered shares of uniQure from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $63.00 to $8.00 in a research report on Thursday, February 29th. Finally, Mizuho lowered their price target on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.75.

View Our Latest Stock Report on uniQure

uniQure Stock Down 2.2 %

The firm has a market cap of $257.80 million, a price-to-earnings ratio of -0.86 and a beta of 1.08. The firm’s fifty day moving average is $4.89 and its two-hundred day moving average is $5.72. The company has a debt-to-equity ratio of 0.70, a current ratio of 9.39 and a quick ratio of 9.27.

uniQure (NASDAQ:QUREGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.05). The company had revenue of $8.49 million during the quarter, compared to analyst estimates of $2.58 million. uniQure had a negative return on equity of 121.60% and a negative net margin of 1,562.22%. On average, sell-side analysts expect that uniQure will post -4.5 EPS for the current fiscal year.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP acquired a new stake in uniQure in the 4th quarter valued at about $26,572,000. 683 Capital Management LLC lifted its holdings in uniQure by 21.6% in the 3rd quarter. 683 Capital Management LLC now owns 1,575,000 shares of the biotechnology company’s stock valued at $10,568,000 after acquiring an additional 280,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after acquiring an additional 109,740 shares during the last quarter. Barclays PLC lifted its holdings in uniQure by 527.8% in the 3rd quarter. Barclays PLC now owns 989,562 shares of the biotechnology company’s stock valued at $6,641,000 after acquiring an additional 831,929 shares during the last quarter. Finally, Citigroup Inc. lifted its holdings in uniQure by 667.9% in the 3rd quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock valued at $5,143,000 after acquiring an additional 666,696 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Recommended Stories

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.